Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clive Ballard

Showing results (431-440 of 480) with videos related to

Pageof 48
Sort By:
BMJ Open|March 25, 2019
Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's diseaseIvan Koychev, Jennifer Lawson, Tharani Chessell, et al.
BMJ Open|November 18, 2022
Understanding primary care diagnosis and management of sleep disturbance for people with dementia or mild cognitive impairment: a realist review protocolLeanne Greene, Aidin Aryankhesal, Molly Megson, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 22, 2012
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trialRenee Romeo, Martin Knapp, Jennifer Hellier, et al.
Trials|December 6, 2017
PERFECTED enhanced recovery (PERFECT-ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified as experiencing confusion: study protocol for a feasibility cluster randomized controlled trialSimon P Hammond, Jane L Cross, Lee Shepstone, et al.
Translational Psychiatry|October 24, 2019
Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's diseaseByron Creese, Evangelos Vassos, Sverre Bergh, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigmsKrista L Lanctôt, Joan Amatniek, Sonia Ancoli-Israel, et al.
Lancet (London, England)|July 19, 2011
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trialSube Banerjee, Jennifer Hellier, Michael Dewey, et al.
International Psychogeriatrics|July 19, 2022
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trialCatherine Henderson, Martin Knapp, Susan Stirling, et al.
Health Technology Assessment (Winchester, England)|November 6, 2023
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Nicolas Farina, Catherine Henderson, et al.
Trials|June 26, 2016
Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trialClaire A Surr, Rebecca E A Walwyn, Amanda Lilley-Kelly, et al.
Pageof 48

Showing results (431-440 of 480) with videos related to

Sort By:
Pageof 48
BMJ Open|March 25, 2019
Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's diseaseIvan Koychev, Jennifer Lawson, Tharani Chessell, et al.
BMJ Open|November 18, 2022
Understanding primary care diagnosis and management of sleep disturbance for people with dementia or mild cognitive impairment: a realist review protocolLeanne Greene, Aidin Aryankhesal, Molly Megson, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 22, 2012
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trialRenee Romeo, Martin Knapp, Jennifer Hellier, et al.
Trials|December 6, 2017
PERFECTED enhanced recovery (PERFECT-ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified as experiencing confusion: study protocol for a feasibility cluster randomized controlled trialSimon P Hammond, Jane L Cross, Lee Shepstone, et al.
Translational Psychiatry|October 24, 2019
Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's diseaseByron Creese, Evangelos Vassos, Sverre Bergh, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigmsKrista L Lanctôt, Joan Amatniek, Sonia Ancoli-Israel, et al.
Lancet (London, England)|July 19, 2011
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trialSube Banerjee, Jennifer Hellier, Michael Dewey, et al.
International Psychogeriatrics|July 19, 2022
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trialCatherine Henderson, Martin Knapp, Susan Stirling, et al.
Health Technology Assessment (Winchester, England)|November 6, 2023
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Nicolas Farina, Catherine Henderson, et al.
Trials|June 26, 2016
Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trialClaire A Surr, Rebecca E A Walwyn, Amanda Lilley-Kelly, et al.
Pageof 48